Concentra Biosciences LLC, controlled by San Diego's Tang Capital Partners LP, made an unsolicited offer at $3 per share plus ...
We recently published an article titled Was Jim Cramer Right About These 12 Stocks? In this article, we are going to take a ...
As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...
Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding ...
Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share. The stock was up 14% at $2.48 in ...
Select Medical Holdings Corporation (NYSE: SEM) Q4 2024 Earnings Call Transcript February 21, 2025 ...
Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP ...
8d
Shares of Concentra Group Holdings Parent, Inc. (NYSE:CON – Get Free Report) have received a consensus rating of “Buy” from the eight brokerages that are covering the firm, Marketbeat reports. Eight ...
The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback